Wild-type transthyretin cardiac amyloidosis: When is a rare disease no longer a rare disease?

Kshama Wechalekar,^{a,c} and Ashutosh D. Wechalekar^b

^a Department of Nuclear Medicine, Royal Brompton and Harefield NHS Foundation Trust, London, UK

^b National Amyloidosis Centre, University College London, London, UK

^c Department of Nuclear Medicine, Royal Brompton Hospital, London, UK

Received May 21, 2020; accepted May 21, 2020

doi:10.1007/s12350-020-02275-1

See related article, pp. 2845–2856

In this issue of JNC, Cuscaden and colleagues report the prevalence of cardiac uptake (a hallmark of cardiac amyloidosis) in patients undergoing routine ^{99m}Tc-HMDP (hydroxymethylene diphosphonate) and ^{99m}Tc-MDP (methylene diphosphonate) scintigraphy, suggesting a high prevalence of the disease increasing with age.¹

Systemic amyloidoses are group of protein misfolding diseases causing organ dysfunction due to progressive deposition of insoluble amyloid fibril deposits.² The amyloid deposits typically target the heart, kidneys, liver, or nerves. The disorder may be caused by persistent high plasma concentration of normal proteins [AA amyloidosis due to persistent inflammation causing high levels of serum amyloid A (an acute phase reactant)], mutation in a normal protein rendering the protein unstable (hereditary amyloidosis due to mutations in transthyretin or fibrinogen A alpha chain or Apolipoprotein A1), a new abnormal circulating protein (AL amyloidosis due to monoclonal immunoglobulin light chains or LECT2 amyloidosis), and, lastly, due to deposition of a normal plasma protein, for reasons as yet unclear (wild-type transthyretin amyloidosis in heart and seminogelin amyloidosis in seminal vesicles). Diagnosis of amyloidosis is complex and, usually delayed, due to symptoms which mimic

those caused by number of other common disorders. We still lack of a simple serologic test to confirm the diagnosis. Histological demonstration of amyloid deposition by Congo red staining showing typical birefringence under cross-polarized light, the gold standard for amyloid diagnosis, can be difficult in patients with isolated cardiac amyloidosis. Lately, demonstration of the exquisite sensitivity of bone scintigraphic agents for cardiac transthyretin amyloid (ATTR) deposits has been an important step change allowing for non-invasive diagnosis of cardiac ATTR amyloidosis.³

The recognition of the prevalence wild-type ATTR amyloidosis (wtATTR) changed over the last decade.⁴ It was considered a rare clinical entity. Despite autopsy series showing that up to a quarter of all persons aged over 80 years may have ATTR amyloid deposits in the heart,⁵ in the UK, less than 300 new cases were seen at the national referral centre in 2019.⁴ Wider availability of cardiac MRI scanning has allowed for easier diagnosis of cardiac amyloidosis. In the last couple of years, availability of novel therapies that can stabilize the transthyretin molecule⁶ or targeted agents that can block hepatic production of transthyretin^{7,8} have been licenced for wtATTR and hereditary ATTR amyloidosis, respectively. This has spurred a global interest in earlier diagnosis of ATTR cardiac amyloidosis.

The actual incidence/prevalence of wtATTR amyloidosis in the population remains unknown. The study by Cuscaden and colleagues in the current issue of JNC is an important landmark in improving our understanding of prevalence of wtATTR amyloidosis and understanding limitations in the interchangeability of bone tracers for imaging cardiac amyloidosis. They report all patients in their institution who had a bone scan for various indications including metastatic skeletal survey and benign indications such as back pain. Scans were assessed for cardiac uptake. Only 1 out of 3,446

Reprint requests: Kshama Wechalekar, Department of Nuclear Medicine, Royal Brompton Hospital, Sydney Street, London SW3 6NP; K.Wechalekar@rbht.nhs.uk

J Nucl Cardiol 2021;28:2857–9.

1071-3581/\$34.00

Copyright © 2020 American Society of Nuclear Cardiology.

^{99m}Tc-MDP scans showed cardiac uptake suggesting limited ability of this tracer to image cardiac amyloidosis. This confirms previous reports showing limited utility of ^{99m}Tc-MDP for this indication.⁹ Using ^{99m}Tc-HMDP, out of 3,472 scans, cardiac uptake was seen in none of the individuals aged < 65 years, 1.44% in males and 0.17% in females aged ≥ 65 years, and 6.15% in males and 1.69% in females ≥ 85 years. Other studies from Europe have previously reported varying prevalence in their populations. Rapezzi and colleagues reported using ^{99m}Tc-3,3-diphosphono-1,2-propanodicarboxylic acid (^{99m}Tc-DPD), in 12,500 scans at their institution, suggested a lower prevalence of 1.4% among men in the ninth decade.¹⁰ In a cohort of patients aged > 75 years from a Spanish study, the reported prevalence of cardiac uptake by ^{99m}Tc-DPD/HDP/HMDP scintigraphy was 3.88% in males and 0.77% in females, and increased with age, reaching 13.9% in males ≥ 85 year.¹¹ In the study by Cuscaden et al., all patients had SPECT imaging to exclude activity due to cardiac blood pool and true uptake in the myocardium which is most reassuring. However, there are two critical caveats in interpreting this study. Firstly, patients with less than grade 2 uptake were excluded. Early cardiac ATTR (as well as AL and other types of cardiac amyloidosis) may show grade 1 uptake—it is unclear whether the prevalence may be higher as early cases were excluded. Secondly, 7 patients had an underlying monoclonal gammopathy and, in 8/15 positive patients, paraprotein results were not available. In these cases, although the authors assume the diagnosis is ATTR because of scintigraphic parameters, it is critically important to have biopsy confirmation of amyloid fibril type (as clearly stated in the non-biopsy diagnosis of ATTR algorithm) and not assume a diagnosis of cardiac ATTR amyloidosis based on scintigraphy alone—a quarter of AL patients will have grade 2 or greater cardiac uptake (UK amyloidosis centre unpublished data).

What is the implication of the study by Cuscaden and colleagues in a wider context? According to a recent United Nations report,¹² globally, the number of persons aged 80 years or older nearly tripled between 1990 and 2019 from 54 to 143 million; it is projected to triple again between 2019 and 2050 to reach 426 million. Extrapolating from the data reported by Cuscaden et al., it would suggest that there are approximately 8.5 million cases of wtATTR amyloidosis in 2019 increasing to nearly 25 million cases by 2050. Heart failure is a global crisis affecting ~ 26 million persons. If indeed, wtATTR amyloidosis is as prevalent as suggested, then a third of all global burden of heart failure may be directly or indirectly be attributed to cardiac amyloid deposition or, is it the case, that cases with wtATTR amyloidosis are unaccounted in the current statistics and

will add to the global burden of cardiovascular disease. Two things are, however, clear: the genie of wtATTR amyloidosis is out and strategies to diagnose (and treat) this disease on a wider scale are needed in all health care systems. For the former, using bone scintigraphy for cardiac amyloid imaging remains the cheapest and most sensitive tool for early diagnosis; confirmation by following the already-described non-invasive ATTR diagnostic algorithm. Secondly, treatment for wtATTR amyloidosis with tafamidis shows survival benefit which appears greater in patients with early disease and other agents are in the pipeline. Last but not the least, is the issue of treatment costs; treatment for wtATTR is presently benchmarked by rare disease standards. Tafamidis, at a cost of \$225,000 per year, is the most expensive cardiovascular drug ever launched. These costs must be re-evaluated to make ATTR drugs widely available in countries with limited health care resources.

The data from the current study, while improving our understanding of the prevalence of ATTR amyloidosis, need to be reproduced in a larger unselected population study for confirmation. The unequivocal message is wtATTR amyloidosis is common in the ninth (and eighth) decade of life in men. This problem is more pertinent with growing size of aging populations and certainly needs to be addressed.

Disclosure

Kshama Wechalekar and Ashutosh D. Wechalekar have no conflict of interest.

References

1. Cuscaden C, Ramsay SC, Prasad S, Goodwin B, Smith J. Estimation of prevalence of transthyretin (ATTR) cardiac amyloidosis in an Australian subpopulation using bone scans with echocardiography and clinical correlation. *J Nucl Cardiol Off Publ Am Soc Nucl Cardiol* 2020. <https://doi.org/10.1007/s12350-020-02152-x>.
2. Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. *Lancet* 2016;387:2641-54.
3. Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. *Circulation* 2016;133:2404-12.
4. Ravichandran S, Lachmann HJ, Wechalekar AD. Epidemiologic and survival trends in amyloidosis, 1987–2019. *N Engl J Med* 2020;382:1567-8.
5. Tanskanen M, Peuralinna T, Polvikoski T, Notkola IL, Sulkava R, Hardy J, et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: A population-based autopsy study. *Ann Med* 2008;40:232-9.
6. Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with

- transthyretin amyloid cardiomyopathy. *N Engl J Med* 2018;379:1007-16.
7. Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. *N Engl J Med* 2018;379:22-31.
 8. Adams D, Gonzalez-Duarte A, O'Riordan WD, Yang CC, Ueda M, Kristen AV, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. *N Engl J Med* 2018;379:11-21.
 9. Rapezzi C, Gagliardi C, Milandri A. Analogies and disparities among scintigraphic bone tracers in the diagnosis of cardiac and non-cardiac ATTR amyloidosis. *J Nucl Cardiol Off Publ Am Soc Nucl Cardiol* 2019;26:1638-41.
 10. Longhi S, Guidalotti PL, Quarta CC, Gagliardi C, Milandri A, Lorenzini M, et al. Identification of TTR-related subclinical amyloidosis with ^{99m}Tc-DPD scintigraphy. *JACC Cardiovasc Imaging* 2014;7:531-2.
 11. Mohamed-Salem L, Santos-Mateo JJ, Sanchez-Serna J, Hernandez-Vicente A, Reyes-Marle R, Castellon Sanchez MI, et al. Prevalence of wild type ATTR assessed as myocardial uptake in bone scan in the elderly population *Int J Cardiol*. 2018;270:192-6.
 12. 2019 World Population Aging Report. 2019. https://www.un.org/development/desa/pd/sites/www.un.org.development.desa.pd/files/documents/2020/Jan/un_2019_worldpopulationageing_report.pdf. Accessed 30 June 2020.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.